Liquidia Corp

LQDA Nasdaq CIK: 0001819576

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
Mailing Address 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
Phone 919.328.4400
Fiscal Year End 1231
EIN 851710962

Financial Overview

FY2025

$327.93M
Total Assets
$283.19M
Total Liabilities
$190.68M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 16, 2026 View on SEC
4 Insider stock transaction report April 16, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC
4 Insider stock transaction report April 14, 2026 View on SEC

Annual Reports

10-K March 5, 2026
  • Liquidia's core focus is on YUTREPIA (treprostinil) inhalation powder for Pulmonary Arterial Hypertension (PAH), utilizing its proprietary PRINT® technology.
  • The company maintains a strong cash position of approximately $140 million as of December 31, 2025, crucial for ongoing operations and development.
View Analysis

Insider Trading

STRONG SELL 10 insiders 46 recent transactions
View Insider Trading Dashboard

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.